Investor Presentation

Date: August 14, 2026 Ref. No.: KDL/SE/029/2026-27 To, To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, Plot No. C-1, Block G, 25th Floor, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (East) Dalal Street, Mumbai- 400001 Mumbai – 400051 Scrip Code: 543328 NSE Symbol: KRSNAA Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for Investor Presentation. Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the presentation for the Investors/Analysts on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026. Request you to take the same on your records. Thanking you, Yours sincerely, For Krsnaa Diagnostics Limited Sujoy Sudipta Bose Company Secretary and Compliance Officer Encl: As above Q1 FY2026-27 Result Presentation One of INDIA’S LARGEST Integrated Diagnostic Service Provider Disclaimer This presentation contains statements that are “forward-looking statements”, including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements pertaining to Krsnaa Diagnostics’ future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Krsnaa Diagnostics undertakes no obligation to publicly revise any forward-looking statements to reflect future/ likely events or circumstances. © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 221 Mn+ 191 76 8,400+ Tests in CT/ MRI Centres Million+ 64% in 5 Years Patient Touch Points Patients Served YoY Retail Revenue In Last 5 Years Growth Districts 75% States/UT Pathology Labs Presence Centers Cover Rural Presence in India PAN India Areas of India One of India’s largest NABH-accredited Krsnaa Diagnostics is one of the fastest tele-radiology reporting hubs with growing and the largest Integrated inherent capability & capacity to diagnostic service provider which The workforce comprises 350+ Provides quality care, accessibility, process X-rays, CT scans, and MRI scans, includes radiology, pathology and tele- radiologists, 100+ pathologists, and accuracy at affordable rates serving patients at the remotest radiology and 3,000+ qualified across various segments with a locations in real-time. professionals, including clinicians, focus on the Public-Private technicians and operators Partnership model © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 Q1 FY27 Financial Performance Particulars Q1 FY27 Q1 FY26 Growth Particulars Q1 FY27 Q1 FY26 Growth Revenue 2,355 1,930 22% No. of Test Performed 16.1 15.8 2% (Mn) EBIDTA 588 524 12% No. of Patient Served 5.1 5.0 2% (Mn) EBIDTA Margin 25% 27% (221 bps) NABL Accreditation 54 54 - (Pathology lab) PAT 166 205 (19%) NABH Accreditation 66 31 113% PAT Margin 7% 11% (360 bps) (Radiology Centre) The moderation in margins is primarily a function of the upfront fixed cost base of Rajasthan laboratories, equipment, manpower and logistics being carried ahead of full utilisation. Note: 1. Financial results of the Company are best monitored on an annual basis, as there is a certain level of cyclicity in business, and specific quarter performance may be impacted by specific events in that quarter 2. EBIDTA is excluding CSR & ESOP 3. INR in mn except EPS, NABL & NABH © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 4 Retail Business Summary Revenue Retail Revenue Retail Revenue Patient Count Test Volume Per Patient Contribution to (INR Mn) (Mn) (Mn) (INR) Group Revenue 193 0.21 0.47 950 931 0.32 Q1 FY26 Q1 FY27 118 0.12 1% 8% Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Up 64% YoY Up 75% YoY Up 47% YoY Optimizing Value Stronger revenues driven by higher Higher test volumes reflect deeper More patients trusting our services Focused on affordability while RPL Krsnaa patient engagement and expanded penetration and improved every day maintaining quality and trust reach accessibility Expanding Deepening Enhancing Driving One Year. Multiple Milestones. Footprint Patient Trust Accessibility Sustainable Growth More patients. Better experience. Stronger foundation Wider reach across Accelerating Retail Excellence. More relationships. Easier access. for long-term value new geographies Stronger trust. Greater convenience. creation. Growth That Matters. Impact That Lasts. 64% 75% 47% 8% Our retail business is scaling new heights- delivering stronger financial Revenue Growth Patient Count Test Volume Retail Revenue performance while staying true to our purpose of "Let's Do Good." YoY Growth YoY Growth YoY Contribution Q1 FY27 – Network Update THE SCALE-UP From a network of centres to a broader and scaled,diagnostic platform across Radiology and Pathology, built for sustained accessibility. RADIOLOGY PATHOLOGY Resilient scale. Larger ambition. Depth meets last-mile reach. The platform continues to expand despite the Tamil Nadu MRI discontinuation. Rajasthan and strategic alliances have accelerated the platform. CURRENT Q1 FY27 RADIOLOGY FOOTPRINT Count Increase Modality Q1FY27 From Q1FY26 CT 149 +4 200+ 37 Up by 6X 175 Up +54% 8,400+ Up +143% REFERENCE LABS SATELLITE LABS PATIENT TOUCH POINTS CT / MRI MRI 42 +2 ON ORDER-BOOK COMPLETION 6 in Q1 FY26 114 in Q1 FY26 3,479 in Q1 FY26 TELE- 1,516 +15 RADIOLOGY INDIA’S DEEPLY ROOTED ONE OF ASIA’S LARGEST RADIOLOGY PLAYERS AND WIDELY ACCESSIBLE PATHOLOGY PLATFORM The count of radiology and pathology services continues to grow. © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 6 Driving Excellence Through Quality India’s 1st ACR Accredited Company India’s 1st CAP Accredited Lab India’s 1st NABH Accredited at Government Facility Tele-Radiology Hub Service Excellence Pioneers of Indian Diagnostic Industry © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 7 Driving Excellence Through Quality ACCREDITATION LEADER ACCREDITATION FOOTPRINT Krsnaa leads the peer set by a wide margin Total NABL + NABH accreditation count Krsnaa 120 TOTAL ACCREDITATIONS Peer A 53 2.3 × Next Peer Peer B 44 Peer C 42 Peer D 31 66 54 Peer E 27 NABH NABL accredited centers accredited labs Peer F 10 Peer G 7 Largest combined accreditation footprint among tracked peers Krsnaa combines the largest NABL-accredited lab base with the largest NABH-accredited centre base in the tracked peer set. © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 8 Presence - PAN India Well Diversified Regional Revenue Mix Q1 FY27 West South North East Krsnaa Presence India map for representation only, not to scale © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 9 Competitive Advantages THE GROWTH STORY Reach → Capacity → Trust → Cash Conversion NEXT PHASE: CASH GROWTH 01 FOUNDATION 02 SCALE - THE ADVANTAGE 03 WAY FORWARD Buildinga larger and A scaled platform Turn network strength more sustainable cash already in place. into consumer growth. business. 2 Cr+ 30K Patient Doctors 212 → 290+ 191 → 200+ 1,500+ Labs CT / MRI Centres X-ray Centres CASH GROWTH 24×7 · 365 DAYS ENGINE Round-the-clock availability supports convenience and access. NETWORK ×SCALE ×PATIENT TRUST Assurance • Accessible • Affordable [Showing first 8,000 characters — download PDF for full document]